Credit Suisse Keeps a Buy Rating on Puma Biotechnology
In a report released yesterday, Alethia Young from Credit Suisse maintained a Buy rating on Puma Biotechnology (NYSEArca: PBYI), with a price target of $106. The company’s shares closed yesterday at $71.05. According to TipRanks.com, Young is a 3-star analyst with an average return of 2.4% and a …